ZFIN Fish: chodl^ue105/ue105; ml2Tg

ZFIN ID: ZDB-FISH-220811-14

ZFIN ID: ZDB-FISH-220811-14

Fish name:	chodl^ue105/ue105; ml2Tg
Genotype:	chodl^ue105/ue105; ml2Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by chodl^ue105/ue105; ml2Tg
No data available

GENE EXPRESSION
Gene expression in chodl^ue105/ue105; ml2Tg

RNA expression No data available

Protein expression

Antibody	Structure	Conditions	Figures
Ab1-chrna	horizontal myoseptum postsynapse of neuromuscular junction myotome postsynapse of neuromuscular junction	chemical treatment by environment: dipyridamole	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
Ab1-chrna	horizontal myoseptum postsynapse of neuromuscular junction myotome postsynapse of neuromuscular junction	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
znp-1	CaP motoneuron presynapse	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
znp-1	CaP motoneuron presynapse	chemical treatment by environment: dipyridamole	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021

Reporter gene expression

Expressed Gene	Structure	Conditions	Figures
GFP	CaP motoneuron axon	control	Fig. 2. , Fig. 3. , Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
	CaP motoneuron axon	chemical treatment by environment: dipyridamole	Fig. 2. , Fig. 3. , Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021

PHENOTYPE
Phenotype in chodl^ue105/ue105; ml2Tg

Phenotype	Conditions	Figures
CaP motoneuron axon decreased length, abnormal	control	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon decreased length, abnormal	chemical treatment by environment: indometacin	Fig. 2. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chemical treatment by environment: dipyridamole	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chemical treatment by environment: (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	Fig. 2. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon extension decreased process quality, abnormal	chemical treatment by environment: indometacin	Fig. 2. from Oprişoreanu et al., 2021
CaP motoneuron axon extension decreased process quality, abnormal	control	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chemical treatment by environment: dipyridamole	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chemical treatment by environment: (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	Fig. 2. from Oprişoreanu et al., 2021
CaP motoneuron presynapse znp-1 labeling amount, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron presynapse area, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron presynapse area, ameliorated	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
CaP motoneuron presynapse znp-1 labeling increased amount, abnormal	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron presynapse increased area, abnormal	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron presynapse assembly decreased process quality, abnormal	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron synaptic assembly at neuromuscular junction process quality, ameliorated	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
CaP motoneuron synaptic assembly at neuromuscular junction process quality, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction area, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction area, ameliorated	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction increased area, abnormal	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development decreased process quality, abnormal	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development process quality, ameliorated	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development process quality, ameliorated	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021

CITATIONS (1)